ArticleJournal of neuroinflammation2025
Transcriptional and neuroprotective effects of hexokinase-2 inhibitors administered after stroke.
Article in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The zinc-nitric oxide axis in acute brain injury: Convergent oxidative-nitrative stress, peroxynitrite signaling, and therapeutic targets.Redox biology · 2026Review
- Therapeutic Targeting of Microglial Hexokinase-2 Recalibrates Inflammasome Activation and Improves Functional Recovery After Traumatic Brain Injury.bioRxiv : the preprint server for biology · 2026Article
- Hexokinase 2 upregulation is associated with glycolytic reprogramming and neuroinflammation in hypoxic-ischemic brain damage: a therapeutic target for early intervention.Frontiers in immunology · 2026Article
- The spatiotemporal dynamic evolution of post-stroke neuroinflammation: energy metabolism mechanisms of acute response and chronic progression.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe delayed inflammatory response induced by stroke can cause secondary injury to peri-infarct tissue. Microglia and other immune cells that mediate this injury require increased glycolytic flux for pro-inflammatory activation. These cells, unlike neurons, astrocytes, and most other cell types, utilize hexokinase-2 (HK2) rather than hexokinase-1 for glycolysis. Accordingly, HK2 inhibitors may selectively target immune cells to suppress post-stroke inflammation. Here we compared the effects of the non-selective hexokinase inhibitor 2-deoxyglucose to the HK2-selective inhibitors lonidamine and 3-bromopyruvate on gene expression changes and secondary injury after stroke.
methodsStroke was induced in mouse motor cortex by photothrombosis, and the hexokinase inhibitors were administered intraperitoneally beginning three hours after stroke. Gene expression in microglia and neurons was evaluated in the adjacent and more distant peri-infarct cortex using in situ spatially defined cell type-specific whole transcriptomic profiling. Tissue injury was quantified using immunohistochemical methods, and mouse functional impairment was assessed over two weeks after stroke by the cylinder, rotating beam, and skilled reaching tasks.
resultsPeri-infarct microglia exhibited an upregulation in pro-inflammatory gene expression, while neighboring neurons showed an upregulation in cell stress/death pathways. These changes were spatially dependent, being greatest adjacent to the infarct edge. The microglial gene expression changes correlated with both morphological activation and increased CD11b expression. The three hexokinase inhibitors had similar effects on gene expression, consistent with a shared mechanism of action. They suppressed pro-inflammatory gene upregulation in peri-infarct microglia, attenuated the cell stress responses in neighboring neurons, and had minimal effect on gene expression in uninjured cortex, with the HK2-selective inhibitors having greater anti-inflammatory effects than 2-deoxyglucose. The HK2-selective inhibitors were also more effective in suppressing microglial morphology changes and CD11b expression, and in suppressing oxidative stress and neurite loss in peri-infarct neurons. Mice treated with the HK2 inhibitor 3-bromopyruvate for four days after stroke showed long-term improvement in functional outcomes.
conclusionsThese findings confirm an essential role for glycolysis in post-stroke, pro-inflammatory microglial activation. Selective HK2 inhibitors provide a clinically applicable approach for suppressing microglial activation and thereby improving outcomes after stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.